Characteristics at baseline
The median age was 44 years (interquartile range (IQR): 36–52) in the integrated HCV treatment group. Of those, 73% were male, and 58% had injected drugs recently. In the standard HCV treatment group, the median age was 42 years (IQR 34–49), 81% were male, and 64% had injected drugs recently. HCV genotype 3 was most prevalent, representing 65% of participants in the integrated HCV treatment group and 61% in the standard HCV treatment group.